Olorofim Phase IIb trial shows efficacy in invasive fungal disease for patients with limited treatment options
Researchers from KU Leuven, the University of California Davis Medical Center, the University of Cologne, and over 20 collaborating institutions report that the antifungal olorofim demonstrated efficacy and tolerability in ...
